[
  {
    "ts": null,
    "headline": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference",
    "summary": "NEW YORK, January 06, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PST.",
    "url": "https://finnhub.io/api/news?id=ec6f36301e5024696d246411ee6c33fd1873c128d5f2b55f6fb9b66948eda9f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736175600,
      "headline": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference",
      "id": 132288291,
      "image": "https://media.zenfs.com/en/business-wire.com/ec36949c044799fa8d1b1310897da5c6",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, January 06, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PST.",
      "url": "https://finnhub.io/api/news?id=ec6f36301e5024696d246411ee6c33fd1873c128d5f2b55f6fb9b66948eda9f1"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (NYSE:PFE) the Best January Dividend Stock to Buy?",
    "summary": "We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other January dividend stocks. In 2024, dividend stocks fell short of investor expectations, largely due to the continuing AI boom and a heightened interest […]",
    "url": "https://finnhub.io/api/news?id=4a0e5ff370994a3a6c58027f02048c665b552d3f67e16a684aef50cdac826d8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736175556,
      "headline": "Is Pfizer Inc. (NYSE:PFE) the Best January Dividend Stock to Buy?",
      "id": 132288292,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other January dividend stocks. In 2024, dividend stocks fell short of investor expectations, largely due to the continuing AI boom and a heightened interest […]",
      "url": "https://finnhub.io/api/news?id=4a0e5ff370994a3a6c58027f02048c665b552d3f67e16a684aef50cdac826d8f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study",
    "summary": "A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID. The study documents mixed outcomes among 13 participants, with some reporting meaningful symptom relief and others seeing little to no benefit. The findings underscore the need for more robust clinical research to evaluate the drug's efficacy in managing persistent symptoms of the condition. Also Read: Pfizer's Paxl",
    "url": "https://finnhub.io/api/news?id=88afbcc479231b0f3c0d87a4d426b4af2991941ad2f3c3fe72d86399f0f3b27d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736171528,
      "headline": "Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study",
      "id": 132288294,
      "image": "https://media.zenfs.com/en/Benzinga/708b814de3dd974f1d7f179b4222a449",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID. The study documents mixed outcomes among 13 participants, with some reporting meaningful symptom relief and others seeing little to no benefit. The findings underscore the need for more robust clinical research to evaluate the drug's efficacy in managing persistent symptoms of the condition. Also Read: Pfizer's Paxl",
      "url": "https://finnhub.io/api/news?id=88afbcc479231b0f3c0d87a4d426b4af2991941ad2f3c3fe72d86399f0f3b27d"
    }
  },
  {
    "ts": null,
    "headline": "Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes",
    "summary": "We have been writing about Viatris since 2021, and it is now on our radar as a potential stock to buy. Read the full analysis update on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=2645aa1ed1961fb4d99cc4b19a6bb2bcf8a799d68c7ebb5347bfb6f25b7b9523",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736171200,
      "headline": "Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes",
      "id": 132289415,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155748151/image_1155748151.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "We have been writing about Viatris since 2021, and it is now on our radar as a potential stock to buy. Read the full analysis update on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=2645aa1ed1961fb4d99cc4b19a6bb2bcf8a799d68c7ebb5347bfb6f25b7b9523"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Down and Out. Opportunities Abound.",
    "summary": "Donald Trump’s election win prompted even more bullishness in a stock market that was already up significantly for the year.  For healthcare investors, though, it represented yet another reason to dump some stock.  Trump’s appointment of industry skeptics like  Robert F. Kennedy Jr.,  alongside broader expectations of a Republican crackdown on programs like Medicaid and Obamacare, has prompted a selloff in everything from hospitals to pharmaceuticals, health insurers and biotech.",
    "url": "https://finnhub.io/api/news?id=5ecfaab583f6fb045d9a38e85ba1f30c96ba7ed3da5389896f8a76e88f3a43da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736164800,
      "headline": "Healthcare Stocks Are Down and Out. Opportunities Abound.",
      "id": 132285420,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Donald Trump’s election win prompted even more bullishness in a stock market that was already up significantly for the year.  For healthcare investors, though, it represented yet another reason to dump some stock.  Trump’s appointment of industry skeptics like  Robert F. Kennedy Jr.,  alongside broader expectations of a Republican crackdown on programs like Medicaid and Obamacare, has prompted a selloff in everything from hospitals to pharmaceuticals, health insurers and biotech.",
      "url": "https://finnhub.io/api/news?id=5ecfaab583f6fb045d9a38e85ba1f30c96ba7ed3da5389896f8a76e88f3a43da"
    }
  }
]